A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Phase of Trial: Phase III/IV
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Hypoparathyroidism
- Focus Therapeutic Use
- Sponsors Shire; Shire Human Genetic Therapies
- 11 Oct 2018 Planned End Date changed from 1 Jun 2021 to 26 Dec 2020.
- 11 Oct 2018 Planned primary completion date changed from 2 Mar 2021 to 26 Dec 2020.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.